SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934
Date of Report (Date of earliest event reported)
August 31, 1995
---------------
Amgen Inc.
------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-12477 95-3540776
------------------------------------------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
1840 Dehavilland Drive, Thousand Oaks, California 91320-1789
------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(805) 447-1000
--------------
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. OTHER EVENTS
------------
Amgen Inc. (the "Company") and one of its licensees,
Ortho Pharmaceutical Corporation, a subsidiary of Johnson &
Johnson ("Johnson & Johnson"), are parties to an arbitration
proceeding described in the Company's Form 10-K for the year
ended December 31, 1994 and the Company's Form 10-Q for the
period ended June 30, 1995. On August 31, 1995, the Company
filed a demand in the arbitration seeking: (1) termination
of the product license agreement between the Company and
Johnson & Johnson, (2) an accounting of Johnson & Johnson's
spillover sales and (3) damages. The Company is unable to
predict at this time the outcome of this demand or when it
will be resolved.
<PAGE>
Signatures
----------
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
Amgen Inc.
-----------------------------------
(Registrant)
September 1, 1995 /s/ Robert S. Attiyeh
----------------- -----------------------------------
(Date) (Signature)
Robert S. Attiyeh
Senior Vice President
Finance and Corporate Development,
and Chief Financial Officer
